Evommune Statistics
Total Valuation
Evommune has a market cap or net worth of $823.74 million. The enterprise value is $621.39 million.
Important Dates
The last earnings date was Thursday, May 7, 2026, after market close.
| Earnings Date | May 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Evommune has 36.02 million shares outstanding. The number of shares has increased by 829.54% in one year.
| Current Share Class | 36.02M |
| Shares Outstanding | 36.02M |
| Shares Change (YoY) | +829.54% |
| Shares Change (QoQ) | +70.26% |
| Owned by Insiders (%) | 2.59% |
| Owned by Institutions (%) | 61.11% |
| Float | 19.96M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 82.37 |
| Forward PS | n/a |
| PB Ratio | 2.70 |
| P/TBV Ratio | 2.70 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 62.14 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 20.36, with a Debt / Equity ratio of 0.03.
| Current Ratio | 20.36 |
| Quick Ratio | 19.94 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -29,997.67 |
Financial Efficiency
Return on equity (ROE) is -44.95% and return on invested capital (ROIC) is -32.30%.
| Return on Equity (ROE) | -44.95% |
| Return on Assets (ROA) | -29.72% |
| Return on Invested Capital (ROIC) | -32.30% |
| Return on Capital Employed (ROCE) | -28.86% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | $208,333 |
| Profits Per Employee | -$1.58M |
| Employee Count | 48 |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 24.25 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 46.33 |
| Average Volume (20 Days) | 405,614 |
Short Selling Information
The latest short interest is 3.25 million, so 9.02% of the outstanding shares have been sold short.
| Short Interest | 3.25M |
| Short Previous Month | 3.31M |
| Short % of Shares Out | 9.02% |
| Short % of Float | 16.28% |
| Short Ratio (days to cover) | 11.75 |
Income Statement
In the last 12 months, Evommune had revenue of $10.00 million and -$75.99 million in losses. Loss per share was -$5.36.
| Revenue | 10.00M |
| Gross Profit | 10.00M |
| Operating Income | -89.99M |
| Pretax Income | -75.99M |
| Net Income | -75.99M |
| EBITDA | -88.63M |
| EBIT | -89.99M |
| Loss Per Share | -$5.36 |
Full Income StatementBalance Sheet
The company has $211.46 million in cash and $9.11 million in debt, with a net cash position of $202.35 million or $5.62 per share.
| Cash & Cash Equivalents | 211.46M |
| Total Debt | 9.11M |
| Net Cash | 202.35M |
| Net Cash Per Share | $5.62 |
| Equity (Book Value) | 304.56M |
| Book Value Per Share | 8.46 |
| Working Capital | 205.25M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$80.05 million and capital expenditures -$318,000, giving a free cash flow of -$80.36 million.
| Operating Cash Flow | -80.05M |
| Capital Expenditures | -318,000 |
| Depreciation & Amortization | 1.36M |
| Net Borrowing | -464,000 |
| Free Cash Flow | -80.36M |
| FCF Per Share | -$2.23 |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -899.93% |
| Pretax Margin | -759.87% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Evommune does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -829.54% |
| Shareholder Yield | -829.54% |
| Earnings Yield | -9.22% |
| FCF Yield | -9.76% |
Analyst Forecast
The average price target for Evommune is $52.25, which is 128.47% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $52.25 |
| Price Target Difference | 128.47% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (5Y) | 84.66% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Evommune has an Altman Z-Score of 21.61 and a Piotroski F-Score of 1.
| Altman Z-Score | 21.61 |
| Piotroski F-Score | 1 |
